Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease

LillyEli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system. The goal of the collaboration is to develop a therapeutic approach for Parkinson's disease that combines the strengths of Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

"We believe we have biosynthetically engineered this GDNF variant to overcome technical hurdles of previous research in this area and are hopeful that early testing of our biologic with Medtronic's device will provide the necessary data to safely advance into human studies," said Michael L. Hutton, Ph.D., chief scientific officer of the neurodegeneration team at Lilly. "By collaborating with Medtronic from the earliest phase of research, we are maximizing the potential for this therapy's efficient and effective development."

Parkinson's disease is a neurodegenerative condition caused by progressive loss of neurons in the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordination of movement. As a result, patients with Parkinson's disease experience balance problems, tremors and muscular stiffness, among other symptoms which worsen over time. It is estimated that 7 million to 10 million people worldwide are living with Parkinson's disease(1) and there is no cure. Around the world, April is Parkinson's Awareness Month.

Applying its expertise in biotechnology, Lilly has designed its GDNF variant with the intent to achieve increased distribution in targeted brain regions. Medtronic has developed a drug pump and specially designed catheter to enable precise delivery of the GDNF variant into a targeted area of the brain consistently over time. This combination of a novel GDNF variant, paired with an optimized delivery system, has the potential to impact the neurodegeneration that leads to worsening symptoms and progression of Parkinson's disease.

"Our collaboration with Lilly is bringing together the expertise of both companies to develop a new approach to the treatment of Parkinson's disease," said Steve Oesterle, M.D., senior vice president of Medicine and Technology at Medtronic. "One of the most significant challenges in delivering a biologic treatment for neurodegenerative diseases is crossing the blood brain barrier. We have extensive experience in targeted drug delivery and technology that allow delivery of therapeutic agents directly to the brain."

"While a potential treatment approach resulting from this research is many years away, we are heartened by Lilly and Medtronic's commitment to develop a neurotrophic-based therapy for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation for Parkinson's Research. "Our foundation has funded separate, ongoing work in neurotrophic factors for years, and we continue to believe in their promise to lead to a critically needed disease-modifying treatment for Parkinson's."

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

About Medtronic
Medtronic, Inc., headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world.

1. The Parkinson's Disease Foundation, http://www.pdf.org/en/parkinson_statistics. Accessed 3/18/2011.

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...